Shots:
- Herantis has dosed first pts with HER-096, a synthetic peptidomimetic in final arm of its P-Ib trial for Parkinson’s disease
- The P-Ib trial consists of 2 parts, with the 1st assessing the safety & PK properties of 300mg HER-096 (SC) & Part 2 evaluating HER-096 vs PBO in 2 Arms along with selected biomarkers to identify novel treatment-response markers in Parkinson’s disease
- The 1st arm (n=12, 8 on 200mg HER-096, 4 on PBO) will receive HER-096 Q2W for 4wks. Following DSMB recommendations, the trial proceeded to the final arm, with pts receiving 300mg HER-096 (Q2W) for 4wks.; topline data is expected in Sep 2025
Ref: GlobeNewswire | Image: Herantis Pharma | Press Release
Related News:- Orion Pharma Collaborates with Criceto for Aporon to Treat OFF Episodes in Parkinson’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
